Mayne Pharma GroupASX:MYX +7.53%51 Quick Ratio is 1.14 as of Dec. 2025, which is 24% below its 10-year median of 1.50. GuruFocus rates ASX:MYX with a GF Score™ of 51/100 and a GF Value™ of A$5.31 (Possible Value Trap). The stock has 3 warning signs investors should review. Among 120 Medical Distribution companies, Mayne Pharma Group ranks better than 55.83% on this metric.
Mayne Pharma Group has a quick ratio of 1.14. It generally indicates good short-term financial strength.
The historical rank and industry rank for Mayne Pharma Group's Quick Ratio or its related term are showing as below:
ASX:MYX'
s Quick Ratio Range Over the Past 10 Years
Min: 0.66 Med: 1.5 Max: 2.22
Current: 1.14
During the past 13 years, Mayne Pharma Group's highest Quick Ratio was 2.22. The lowest was 0.66. And the median was 1.50.
ASX:MYX's Quick Ratio is ranked better than 55.83% of 120
companies
in the Medical Distribution industry
Industry Median: 1.055
vs ASX:MYX: 1.14
Mayne Pharma Group (ASX:MYX) Quick Ratio Explanation
The quick ratio is more conservative than the Current Ratio because it excludes inventories from current assets. The ratio derives its name presumably from the fact that assets such as cash and marketable securities are quick sources of cash. Inventories generally take time to be converted into cash, and if they have to be sold quickly, the company may have to accept a lower price than book value of these inventories. As a result, they are justifiably excluded from assets that are ready sources of immediate cash.
In general, low or decreasing quick ratios generally suggest that a company is over-leveraged, struggling to maintain or grow sales, paying bills too quickly or collecting receivables too slowly. On the other hand, a high or increasing quick ratio generally indicates that a company is experiencing solid top-line growth, quickly converting receivables into cash, and easily able to cover its financial obligations. Such companies often have faster inventory turnover and cash conversion cycles.
The higher the quick ratio, the better the company's liquidity position.
Mayne Pharma Group Quick Ratio Related Terms
Mayne Pharma Group Quick Ratio Historical Data
* Premium members only.
The historical data trend for Mayne Pharma Group's Quick Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Distribution subindustry, Mayne Pharma Group's Quick Ratio, along with its competitors' market caps and Quick Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Mayne Pharma Group Quick Ratio vs Medical Distribution Industry
For the Medical Distribution industry and Healthcare sector, Mayne Pharma Group's Quick Ratio distribution charts can be found below:
* The bar in red indicates where Mayne Pharma Group's Quick Ratio falls into.
The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. For this reason, the ratio excludes inventories from current assets.
Mayne Pharma Group's Quick Ratio for the fiscal year that ended in Jun. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Mayne Pharma Group (ASX:MYX) has a Quick Ratio of 1.14 as of Dec. 2025. Quick ratio is the ratio of current assets less inventory to current liabilities. View historical data on Mayne Pharma Group and its competitors. This is 24% below median its historical median of 1.50. Over the past decade, Mayne Pharma Group's Quick Ratio has ranged from 0.66 to 2.22. According to the industry distribution chart, Mayne Pharma Group ranks #53 out of 120 companies in the Medical Distribution industry, placing it in the top 44.2%.
Is Mayne Pharma Group's Quick Ratio too high?
Mayne Pharma Group's current Quick Ratio of 1.14 is 24% below median its 10-year median of 1.50. Over the past 10 years, this metric has ranged from a low of 0.66 to a high of 2.22. The Medical Distribution industry median Quick Ratio is 1.06. Mayne Pharma Group's value of 1.14 is 8.1% above this industry median. Based on the distribution chart, Mayne Pharma Group ranks #53 out of 120 companies in the Medical Distribution industry, which is above the industry midpoint. Overall, Mayne Pharma Group has a GF Score™ of 51/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Mayne Pharma Group's Quick Ratio compare to MCK and COR?
According to the Medical Distribution industry distribution chart, Mayne Pharma Group ranks #53 out of 120 companies for Quick Ratio. This puts Mayne Pharma Group in the upper half of its industry. The industry median Quick Ratio is 1.06. Mayne Pharma Group's value of 1.14 is 8.1% above this benchmark. Historically, Mayne Pharma Group's own Quick Ratio has ranged from 0.66 to 2.22 over the past decade. While the company's 10-year median is 1.50 vs. the industry median of 1.06, Mayne Pharma Group has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Quick Ratio for a Medical Distribution company?
The median Quick Ratio among Medical Distribution companies is 1.06, based on 120 companies in the industry. Companies in the top quartile (top 25%) have a Quick Ratio significantly above this median, while those in the bottom quartile fall well below. However, Quick Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Mayne Pharma Group's current Quick Ratio of 1.14 is 8.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Quick Ratio mean?
A high Quick Ratio can signal that a stock is expensive relative to its fundamentals. Quick ratio is the ratio of current assets less inventory to current liabilities. View historical data on Mayne Pharma Group and its competitors. For the Medical Distribution industry, the median Quick Ratio is 1.06 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Mayne Pharma Group's current Quick Ratio is 1.14, which is 24% below median its own 10-year median of 1.50. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Mayne Pharma Group stock overvalued right now?
Based on GuruFocus' analysis, Mayne Pharma Group (ASX:MYX) is currently considered Possible Value Trap. The stock's GF Value™ is A$5.31, compared to a current price of A$2.57 — trading 51.6% below its estimated fair value. The current Quick Ratio is 1.14, which is 24% below median its 10-year median of 1.50 and 8.1% above the Medical Distribution industry median of 1.06. Mayne Pharma Group's overall GF Score™ is 51/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Quick Ratio calculated?
Quick Ratio is calculated from a company's financial statements. For Mayne Pharma Group (ASX:MYX), the current Quick Ratio is 1.14 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Mayne Pharma Group (ASX:MYX) Overvalued in 2026?
Based on GuruFocus' analysis, Mayne Pharma Group stock appears to be undervalued.
The current stock price of A$2.57 is trading 51.6% below its estimated GF Value™ of A$5.31.
GuruFocus considers Mayne Pharma Group to be Possible Value Trap.
Key valuation signals for ASX:MYX:
Quick Ratio: 1.14 (24% below median its 10-year median of 1.50)
GF Value™: A$5.31 vs. price of A$2.57 (51.6% below fair value)
Industry Position: 8.1% above the Medical Distribution median (#53 of 120)
No single metric tells the full story. See the ASX:MYX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Mayne Pharma Group Ltd is a specialty pharmaceutical company focused on commercializing novel and generic pharmaceuticals It has a Forty-year track record of innovation and success in developing oral drug delivery systems. The Company's Business consists of three operating segments being International, Women's Health and Dermatology. The Dermatologysegment distributes dermatology products (branded and generic) in the U.S. on a portfolio basis, The Women's Health segment distributes branded women's health products in the U.S. International's segment revenue and gross profit are derived principally from the Australian manufacture and sale of branded and generic pharmaceutical products.
51GF Score
Get the complete analysis for ASX:MYX
Quick Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:MYX has been successfully added to your 
